Citation: Bing Ji, Jiawei Bai, Luis A J Mur, Mengjia Zou, Jiwan Han, Rui Gao, Qing Yang. Mathematical modelling of Her2 (ErbB2) PI3K/AKT signalling pathways during breast carcinogenesis to include PTPD2[J]. AIMS Mathematics, 2020, 5(5): 4946-4958. doi: 10.3934/math.2020316
[1] | K. Polyak, Heterogeneity in breast cancer, J. Clin. Invest., 121 (2011), 3786-3788. doi: 10.1172/JCI60534 |
[2] | E. M. Bublil, Y. Yarden, The EGF receptor family: spearheading a merger of signaling and therapeutics, Curr. Opin. Cell Biol., 19 (2007), 124-134. doi: 10.1016/j.ceb.2007.02.008 |
[3] | D. J. Slamon, G. M. Clark, S. G. Wonf, et al. HUMAN-BREAST CANCER - CORRELATION OF RELAPSE AND SURVIVAL WITH AMPLIFICATION OF THE HER-2 NEU ONCOGENE, Science, 235 (1987), 177-182. doi: 10.1126/science.3798106 |
[4] | D. H. Yu, M. C. Hung, Overexpression of ErbB2 in cancer and ErbB2-targeting strategies, Oncogene, 19 (2000), 6115-6121. doi: 10.1038/sj.onc.1203972 |
[5] | W. Tai, R. Mahato, K. Cheng, The role of HER2 in cancer therapy and targeted drug delivery, J. Control RELEASE, 146 (2010), 264-275. doi: 10.1016/j.jconrel.2010.04.009 |
[6] | F. Xu, L. Na, Y. Li, et al. Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours, CELL Biosci., 10 (2020), 1-12. doi: 10.1186/s13578-019-0370-3 |
[7] | B. Ji, Y. Zhang, C. Zhen, et al. Mathematical modelling of bone remodelling cycles including the NF kappa B signalling pathway, Comput. Biol. Med., 107 (2019), 257-264. doi: 10.1016/j.compbiomed.2019.03.003 |
[8] | B. Ji, J. Chen, C. Zhen, et al. Mathematical modelling of the role of Endo180 network in the development of metastatic bone disease in prostate cancer, Comput. Biol. Med., 117 (2020), 103619. |
[9] | B. Schoeberl, C. Eichler-Jonsson, E. D. Gilles, et al. Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors, Nat. Biotechnol., 20 (2002), 370-375. doi: 10.1038/nbt0402-370 |
[10] | M. Hatakeyama, S. Kimura, T. Naka, et al. (2003) A computational model on the modulation of mitogen-activated protein kinase (MAPK) and Akt pathways in heregulin-induced ErbB signalling, Biochem. J., 373 (2003), 451-463. |
[11] | G. Koh, H. F. C. Teong, M. V. Clément, et al. A decompositional approach to parameter estimation in pathway modeling: A case study of the Akt and MAPK pathways and their crosstalk, Bioinformatics, 22 (2006), e271-e280. |
[12] | S. Itani, J. Gray, C. J. Tomlin, An ODE model for the HER2/3-AKT signaling pathway in cancers that overexpress HER2, Proc. 2010 Am. Control Conf., (2010), 1235-1241. |
[13] | D. C. Kirouac, J. Y. Du, J. Lahdenranta, et al. Computational Modeling of ERBB2-Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors, Sci. Signal., 6 (2013), ra68. |
[14] | E. Shankar, M. C. Weis, J. Avva, et al. Complex Systems Biology Approach in Connecting PI3K-Akt and NF-kappa B Pathways in Prostate Cancer, CELLS, 8 (2019). |
[15] | Z. Eroglu, T. Tagawa, G. Somlo, Human Epidermal Growth Factor Receptor Family-Targeted Therapies in the Treatment of HER2-Overexpressing Breast Cancer, Oncologist, 19 (2014), 135-150. doi: 10.1634/theoncologist.2013-0283 |
[16] | M. Ramesh, N. Krishnan, S. K. Muthuswamy, et al. A novel phosphatidic acid-protein-tyrosine phosphatase D2 axis is essential for ERBB2 signaling in mammary epithelial cells, J. Biol. Chem., 290 (2015), 9646-9659. doi: 10.1074/jbc.M114.627968 |
[17] | F. J. Esteva, H. Guo, S. Zhang, et al. PTEN, PIK3CA, p-AKT, and p-p70S6K Status Association with Trastuzumab Response and Survival in Patients with HER2-Positive Metastatic Breast Cancer, Am. J. Pathol., 177 (2010), 1647-1656. doi: 10.2353/ajpath.2010.090885 |
[18] | R. Slaaby, T. Jensen, H. S. Hansen, et al. PLD2 complexes with the EGF receptor and undergoes tyrosine phosphorylation at a single site upon agonist stimulation, J. Biol. Chem., 273 (1998), 33722-33727. doi: 10.1074/jbc.273.50.33722 |
[19] | R. C. Bruntz, C. W. Lindsley, H. A. Brown, Phospholipase D Signaling Pathways and Phosphatidic Acid as Therapeutic Targets in Cancer, Pharmacol. Rev., 66 (2014), 1033-1079. doi: 10.1124/pr.114.009217 |
[20] | Y. Yarden, M. X. Sliwkowski, Untangling the ErbB signalling network, Nat. Rev. Mol. CELL Biol., 2 (2001), 127-137. doi: 10.1038/35052073 |
[21] | J. Saez-Rodriguez, A. MacNamara, S. Cook, Modeling Signaling Networks to Advance New Cancer Therapies, ANNU. REV. BIOMED. ENG., 17 (2015), 143-163. doi: 10.1146/annurev-bioeng-071813-104927 |
[22] | A. Eladdadi, D. Isaacson, A mathematical model for the effects of HER2 overexpression on cell proliferation in breast cancer, Bull. Math. Biol., 70 (2008), 1707-1729. doi: 10.1007/s11538-008-9315-4 |
[23] | C. Frank, H. Keilhack, F. Opitz, et al. Binding of phosphatidic acid to the protein-tyrosine phosphatase SHP-1 as a basis for activity modulation, Biochemistry, 38 (1999), 11993-12002. doi: 10.1021/bi982586w |
[24] | P. E. Selvy, R. R. Lavieri, C. W. Lindsley, et al. Phospholipase D: Enzymology, Functionality, and Chemical Modulation, Chem. Rev., 111 (2011), 6064-6119. doi: 10.1021/cr200296t |
[25] | Y. A. Adi, F. A. Kusumo, L. Aryati, et al. A Mathematical Model of Phosphorylation AKT in Acute Myeloid Leukemia, SYMPOSIUM ON BIOMATHEMATICS (SYMOMATH 2015), 1723 (2016), 030001. |
[26] | L. Lenoci, M. Duvernay, S. Satchell, et al. Mathematical model of PAR1-mediated activation of human platelets, Mol. Biosyst., 7 (2011), 1129-1137. doi: 10.1039/c0mb00250j |
[27] | R. J. Buxeda, J. T. Nickels, C. J. Belunis, et al. PHOSPHATIDYLINOSITOL 4-KINASE FROM SACCHAROMYCES-CEREVISIAE. KINETIC-ANALYSIS USING TRITON X-100 PHOSPHATIDYLINOSITOL-MIXED MICELLES, J. Biol. Chem., 266 (1991), 13859-13865. |
[28] | L. G. Henage, J. H. Exton, H. A. Brown, Kinetic analysis of a mammalian phospholipase D - Allosteric modulation by monomeric GTPases, protein kinase C, and polyphosphoinositides, J. Biol. Chem., 281 (2006), 3408-3417. doi: 10.1074/jbc.M508800200 |
[29] | W. H. Tan, A. S. Popel, F. Mac Gabhann, Computational Model of Gab1/2-Dependent VEGFR2 Pathway to Akt Activation, PLoS One, 8 (2013), 1-17. |
[30] | A. De Luca, M. R. Maiello, A. D'Alessio, et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches, Expert Opin. Ther. Tar., 16 (2012), S17-S27. |
[31] | M. Kanehisa, S. Goto, Y. Sato, et al. KEGG for integration and interpretation of large-scale molecular data sets, Nucleic Acids Res., 40 (2012), D109-D114. |
[32] | A. Dittrich, H. Gautrey, D. Browell, et al. The HER2 Signaling Network in Breast Cancer-Like a Spider in its Web, J. Mammary Gland Biol. Neoplasia, 19 (2014), 253-270. doi: 10.1007/s10911-014-9329-5 |